Comparison of timolol 0.5% versus desoximetasone 0.25% in the treatment of chronic hand eczema

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210704004

Enrollment

Registered

2021-07-04

Start date

2021-06-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bilateral chronic hand eczema in mild to moderate PGA severity Hand eczema Hand dermatitis Timolol Beta-adrenergic antagonist Beta-blocker Treatment

Interventions

Apply timolol 0.5% all over the area of lesions on one hand twice daily for 8 weeks. Then, apply petroleum ointment for additional 4 weeks.,Apply desoximetasone 0.25% all over the area of lesions on

Active Comparator Drug,Active Comparator Drug

timolol 0.5%,desoximetasone 0.25%

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Bilateral chronic hand eczema in mild to moderate PGA severity without eczema in other areas 2. Participants must have been informed of study procedures and therapies and must have given their written informed consent 3. Participants must be able to read and write in Thai

Exclusion criteria

Exclusion criteria: 1. Pregnancy or lactation 2. Patient who has history of sinus bradycardia, second- or third-degree heart block, overt cardiac failure, or cardiogenic shock 3. Patient who has history of bronchial asthma or chronic obstructive pulmonary disease 4. Use of topical medication (immunosuppressant, retinoid, corticosteroids) 2 weeks before study entry 5. Use of systemic medication (immunosuppressant, retinoid, corticosteroids) or phototherapy 4 weeks before study entry 6. Hypersensitivity to ingredients of timolol or desoximetasone 7. Have any other active skin diseases on the hands such as psoriasis or acute skin infections 8. Previously positive patch test

Design outcomes

Primary

Measure	Time frame
Disease severity baseline Physician global assessment,Clinical outcome baseline, 2nd, 4th, and 8th weeks during treatment and next 4 weeks after discontinuation of the intervention Hand eczema severity index (HECSI),Clinical outcome baseline, 2nd, 4th, 8th and 12th weeks Digital photograph,Subjective outcome baseline, 8th week of treatment, and 4 weeks after treatment cessation Visual analogue scale	—

Measure

Time frame

Disease severity baseline Physician global assessment,Clinical outcome baseline, 2nd, 4th, and 8th weeks during treatment and next 4 weeks after discontinuation of the intervention Hand eczema severity index (HECSI),Clinical outcome baseline, 2nd, 4th, 8th and 12th weeks Digital photograph,Subjective outcome baseline, 8th week of treatment, and 4 weeks after treatment cessation Visual analogue scale

—

Secondary

Measure	Time frame
Adverse events baseline, 2nd, 4th, 8th and 12th weeks Patient reported outcome using a questionnaire interview	—

Countries

Thailand

Contacts

Public ContactPyrapa Jivanantapravat

Division of Dermatology, Chulabhorn International College of Medicine, Thammasat University

pyraps03@gmail.com0256444409

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026